Skip to main content
OpenTrials

Clinical trial condition

Anaplastic Large Cell Lymphoma, ALK-Positive

Explore clinical trials studying Anaplastic Large Cell Lymphoma, ALK-Positive. Study availability and eligibility vary by location and protocol.

13 public trials 4 recruiting studies
Refine in advanced search Browse all conditions

Anaplastic Large Cell Lymphoma, ALK-Positive trial results

Recruiting

A Registry for People With T-cell Lymphoma

NCT05978141

Conditions
Adult T-Cell Leukemia/Lymphoma, Aggressive NK-cell Leukemia, Anaplastic Large Cell Lymphoma, ALK-Positive, +54 more
Locations
  • City of Hope Cancer Center (Data collection only) Duarte, California, United States
  • UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only) San Diego, California, United States
  • University of California San Francisco (Data collection only) San Francisco, California, United States
  • Stanford University Medical Center (Data collection only) Stanford, California, United States
View all 26 locations
View Trial Details
Active, not recruiting

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

NCT02978625

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Anaplastic Large Cell Lymphoma, ALK-Positive, +86 more
Locations
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • Keck Medical Center of USC Pasadena Pasadena, California, United States
View all 36 locations
View Trial Details
Active, not recruiting

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

NCT03113500

Conditions
Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, +26 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
  • M D Anderson Cancer Center Houston, Texas, United States
View Trial Details
Completed

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

NCT03493451

Conditions
ALK-Positive Anaplastic Large Cell Lymphoma, ALK-negative Anaplastic Large Cell Lymphoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma, +36 more
Locations
  • British Columbia Cancer Agency the Vancouver Centre Vancouver, British Columbia, Canada
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Beijing Hospital Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital Beijing, Beijing Municipality, China
View all 24 locations
View Trial Details
Completed

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

NCT01979536

Conditions
Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma, +12 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Kaiser Permanente Downey Medical Center Downey, California, United States
View all 154 locations
View Trial Details

Related conditions